SOLO-2: Overall Survival Data on Olaparib for Relapsed, BRCA-Mutated Ovarian Cancer

May 29, 2020

SOLO-2 is the first phase 3 trial to provide overall survival (OS) data on maintenance PARP inhibitor therapy.

Nationwide Study Shows Cancer Mortality Benefit Following State Medicaid Expansion

May 29, 2020

The study is the first of its kind on a national scale to show the benefit of Medicaid expansion on cancer mortality rates.

ASCO20 Virtual: Study Assesses COVID-19 Clinical Data, Finds Cancer Mortality Links

May 28, 2020

The findings, which were presented virtually in the 2020 ASCO Virtual Scientific Program, included the association between treatment with hydroxychloroquine plus azithromycin and increased risk of death.

ASCO Special Report Offers Guidance on Cancer Care Delivery During Pandemic

May 28, 2020

The American Society of Clinical Oncology (ASCO) recently released a detailed guidance to oncology practices

FDA Approves Olaparib for HRR-Mutated Metastatic Castration-Resistant Prostate Cancer

May 20, 2020

Approximately 20% to 30% of men with metastatic castration-resistant prostate cancer have HRR gene mutation.

FDA OKs Atezolizumab for First-Line Treatment of PD-L1 High NSCLC

May 19, 2020

Atezolizumab demonstrated a significant overall survival benefit in individuals with high PD-L1 expression compared with chemotherapy.

Trastuzumab Deruxtecan Granted Breakthrough Designation for HER2-Mutant Metastatic NSCLC

May 19, 2020

Officials with the FDA have granted breakthrough therapy designation to trastuzumab deruxtecan (Enhertu, AstraZeneca and Daiichi Sankyo) for the treatment of HER2-mutant metastatic non-small cell lung cancer (NSCLC).

FDA Approves Rucaparib for Some Prostate Cancer Types

May 18, 2020

Rucaparib is the first PARP inhibitor that has been approved in a prostate cancer setting.

Fam-trastuzumab Deruxtecan-nxki for HER2-Positive Unresectable or Metastatic Breast Cancer

May 13, 2020

Fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) is indicated for treating adults with unresectable or metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2–based regimens in the setting of metastasis.

Study Explores Racial Inequalities in Liver Cancer Deaths After Launch of Hepatitis C Treatments

May 12, 2020

"A major clinical and public health priority should be to decrease racial inequalities in mortality following the introduction of lifesavings drugs in the United States and worldwide.”